BioSpace News Archive

The global cutaneous squamous cell carcinoma treatment market is likely to show upward revenues curve during the forecast period of 2019 to 2029.

Remarkable growth in number of COVID-19 patients in all worldwide locations is likely to fuel the expansion of the global electric bed market throughout the assessment period 2019–2029.

The demand within the global washable and reusable masks market is growing at a sturdy pace in recent years.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Virtual BioConnect Conference.

Tiragolumab is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation (BTD) and marks the 37th BTD for Genentech’s portfolio of medicines

AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases, announced that Dr. Eduardo Schiffrin, Medical Director, will participate in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Friday, January 8 from 11am Eastern Standard Time.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces it plans to initiate a proof-of-concept clinical trial of SENS-401 to treat CIO in H2 2021.

Sosei Group Corporation announces it is to regain the worldwide rights to its muscarinic agonist programs.

Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today announced that a corporate update will be presented at the 39 th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 4:30pm ET. A live webcast of the event can be acce

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, announced that Sheila Oren, M.D., M.B.A., was appointed Chief Executive Officer of Pharma Two B, effective January 1, 2021.